LTPA2024512I1 - - Google Patents
Info
- Publication number
- LTPA2024512I1 LTPA2024512I1 LTPA2024512C LTPA2024512C LTPA2024512I1 LT PA2024512 I1 LTPA2024512 I1 LT PA2024512I1 LT PA2024512 C LTPA2024512 C LT PA2024512C LT PA2024512 C LTPA2024512 C LT PA2024512C LT PA2024512 I1 LTPA2024512 I1 LT PA2024512I1
- Authority
- LT
- Lithuania
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662398713P | 2016-09-23 | 2016-09-23 | |
| US201762527204P | 2017-06-30 | 2017-06-30 | |
| US201762530683P | 2017-07-10 | 2017-07-10 | |
| US201762539037P | 2017-07-31 | 2017-07-31 | |
| PCT/US2017/052891 WO2018057849A1 (en) | 2016-09-23 | 2017-09-22 | Uses of il-13 antagonists for treating atopic dermatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LTPA2024512I1 true LTPA2024512I1 (https=) | 2024-05-27 |
| LTC3528838I2 LTC3528838I2 (https=) | 2025-10-10 |
Family
ID=60020628
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/US2017/052891T LT3528838T (lt) | 2016-09-23 | 2017-09-22 | Il-13 antagonistų panaudojimas gydant atopinį dermatitą |
| LTPA2024512C LTC3528838I2 (https=) | 2016-09-23 | 2024-04-29 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/US2017/052891T LT3528838T (lt) | 2016-09-23 | 2017-09-22 | Il-13 antagonistų panaudojimas gydant atopinį dermatitą |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US11434286B2 (https=) |
| EP (2) | EP3528838B1 (https=) |
| JP (1) | JP6995844B2 (https=) |
| KR (1) | KR102557643B1 (https=) |
| CN (1) | CN109715201A (https=) |
| AU (1) | AU2017330405B2 (https=) |
| CA (1) | CA3031589C (https=) |
| CY (2) | CY1126255T1 (https=) |
| DK (1) | DK3528838T5 (https=) |
| ES (1) | ES2958593T3 (https=) |
| FI (2) | FI3528838T3 (https=) |
| FR (1) | FR24C1017I2 (https=) |
| HR (1) | HRP20231015T1 (https=) |
| HU (2) | HUE063135T2 (https=) |
| IL (1) | IL265473B2 (https=) |
| LT (2) | LT3528838T (https=) |
| MX (1) | MX2019002672A (https=) |
| NL (1) | NL301269I2 (https=) |
| NZ (1) | NZ790629A (https=) |
| PL (1) | PL3528838T3 (https=) |
| PT (1) | PT3528838T (https=) |
| RS (1) | RS64550B1 (https=) |
| RU (1) | RU2752785C2 (https=) |
| SG (1) | SG11201900845YA (https=) |
| SI (1) | SI3528838T1 (https=) |
| TW (1) | TWI787203B (https=) |
| UA (1) | UA124269C2 (https=) |
| WO (1) | WO2018057849A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6871948B2 (ja) | 2016-04-27 | 2021-05-19 | アッヴィ・インコーポレイテッド | 抗ｉｌ−１３抗体を使用する、ｉｌ−１３活性が有害である疾患の治療方法 |
| PT3528838T (pt) * | 2016-09-23 | 2023-09-04 | Hoffmann La Roche | Utilizações de antagonistas de il-13 para tratamento de dermatite atópica |
| JP2021147383A (ja) * | 2020-03-23 | 2021-09-27 | メドイミューン・リミテッドMedImmune Limited | アトピー性皮膚炎及び関連障害を処置するための方法 |
| KR20230004489A (ko) * | 2020-03-23 | 2023-01-06 | 메디뮨 리미티드 | 아토피 피부염 및 관련 장애의 치료 방법 |
| IL301935A (en) * | 2020-10-09 | 2023-06-01 | Kyowa Kirin Co Ltd | A method for treating an OX40-related disease |
| TW202302104A (zh) * | 2021-02-18 | 2023-01-16 | 美商阿克拉里斯醫療股份有限公司 | Jak 1/3抑制劑的局部配方及其用於治療異位性皮膚炎和其他皮膚狀況之用法 |
| BR112023017490A2 (pt) * | 2021-03-17 | 2023-11-07 | Receptos Llc | Métodos de tratamento de dermatite atópica com anticorpos anti il-13 |
| TWI847170B (zh) * | 2021-07-16 | 2024-07-01 | 美商德米拉股份有限公司 | 用於治療異位性皮炎之il-13抗體 |
| TWI859566B (zh) * | 2021-08-13 | 2024-10-21 | 美商德米拉股份有限公司 | 用於治療異位性皮膚炎之il-13抗體 |
| AU2022345969A1 (en) * | 2021-09-15 | 2024-03-07 | Dermira, Inc. | Il-13 inhibitors for the treatment of prurigo nodularis |
| US20250352644A1 (en) * | 2022-05-05 | 2025-11-20 | Dermira, Inc. | Il-13 antibodies for the treatment of atopic dermatitis |
| EP4540284A2 (en) | 2022-06-17 | 2025-04-23 | Apogee Therapeutics, Inc. | Antibodies that bind interleukin 13 and methods of use |
| US20260078192A1 (en) * | 2022-09-06 | 2026-03-19 | Aslan Pharmaceuticals Pte Ltd | Treatment for sleep loss or sleep disturbance in patients with dermatitis |
| EP4671274A1 (en) | 2023-03-14 | 2025-12-31 | Geovista Inc. | ANTIBODIES THAT BIND SPECIFICALLY TO INTERLEUKIN-13 AND ITS USE |
| KR102773781B1 (ko) | 2023-03-14 | 2025-02-28 | 주식회사 지오비스타 | 인터루킨-13에 특이적으로 결합하는 항체 및 그의 용도 |
| GB202306662D0 (en) | 2023-05-05 | 2023-06-21 | Union Therapeutics As | Dosage regimen |
| KR20250017610A (ko) | 2023-07-27 | 2025-02-04 | 김천균 | 아토피의 치료와 예방용 조성물 및 그 제조방법 |
| AU2024334289A1 (en) | 2023-08-25 | 2026-04-09 | Proteologix Us Inc. | Anti-il-13 multispecific antibody constructs and uses thereof |
| TW202535949A (zh) | 2023-12-20 | 2025-09-16 | 美商必治妥美雅史谷比公司 | 靶向IL-18受體β(IL-18RB)之抗體及相關方法 |
| WO2025155874A1 (en) * | 2024-01-18 | 2025-07-24 | Enveda Therapeutics, Inc. | Methods and compounds for modulating immune response |
| WO2025264960A1 (en) * | 2024-06-21 | 2025-12-26 | Apogee Therapeutics, Inc. | Antibodies that bind il-13 and antibodies that bind ox40l |
| WO2025264972A1 (en) * | 2024-06-21 | 2025-12-26 | Apogee Therapeutics, Inc. | Antibodies that bind il-4r alpha and antibodies that bind |
| WO2026080829A1 (en) * | 2024-10-10 | 2026-04-16 | Apogee Therapeutics, Inc. | Methods of administering antibodies that bind interleukin 13 |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
| DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| ES2248127T3 (es) | 1999-10-04 | 2006-03-16 | Medicago Inc. | Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno. |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING A POLYPEPTIDE |
| EP1240319A1 (en) | 1999-12-15 | 2002-09-18 | Genentech, Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
| JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
| NZ571596A (en) | 2001-08-03 | 2010-11-26 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| CA2463879C (en) | 2001-10-25 | 2012-12-04 | Genentech, Inc. | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
| EP1500400A4 (en) | 2002-04-09 | 2006-10-11 | Kyowa Hakko Kogyo Kk | MEDICAMENT WITH ANTIBODY COMPOSITION |
| BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
| CA2481925A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for patients having human fc.gamma.riiia |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| CA2481658A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to fcy receptor iiia |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
| WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| JPWO2005035778A1 (ja) | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法 |
| US9296820B2 (en) | 2003-11-05 | 2016-03-29 | Roche Glycart Ag | Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| PL3718564T3 (pl) | 2003-12-23 | 2024-03-18 | Genentech, Inc. | Nowe przeciwciała anty-IL 13 i ich zastosowania |
| EP1740615B1 (en) | 2004-03-31 | 2014-11-05 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
| PT1737891E (pt) | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| AR049390A1 (es) | 2004-06-09 | 2006-07-26 | Wyeth Corp | Anticuerpos contra la interleuquina-13 humana y usos de los mismos |
| US20070048785A1 (en) | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| EP2438948B1 (en) | 2004-11-24 | 2016-03-30 | SHL Group AB | Tubular rotator for a medicament injection device, and medicament injection device |
| ATE401921T1 (de) | 2005-06-01 | 2008-08-15 | Shl Medical Ab | Medikamentenabgabevorrichtung |
| JP5026411B2 (ja) | 2005-06-01 | 2012-09-12 | エスエイチエル グループ エービー | 薬物送達装置 |
| AU2006296399B2 (en) | 2005-09-30 | 2011-01-20 | Medimmune Limited | Interleukin-13 antibody composition |
| WO2007045477A2 (en) | 2005-10-21 | 2007-04-26 | Novartis Ag | Human antibodies against il-13 and therapeutic uses |
| ES2577292T3 (es) | 2005-11-07 | 2016-07-14 | Genentech, Inc. | Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso |
| EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
| TW200812616A (en) | 2006-05-09 | 2008-03-16 | Genentech Inc | Binding polypeptides with optimized scaffolds |
| WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| CA2674608A1 (en) | 2007-01-09 | 2008-07-17 | Wyeth | Anti-il-13 antibody formulations and uses thereof |
| CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| FR2944448B1 (fr) | 2008-12-23 | 2012-01-13 | Adocia | Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes. |
| AU2013204900B2 (en) * | 2010-12-16 | 2016-11-10 | Genentech, Inc. | Diagnosis and treatments relating to TH2 inhibition |
| RU2578468C2 (ru) * | 2010-12-16 | 2016-03-27 | Дженентек, Инк. | Способы диагностики и лечения, связанные с ингибированием th2 |
| CA2839493C (en) | 2011-06-17 | 2016-02-09 | Shl Group Ab | Injection device |
| WO2012173554A1 (en) | 2011-06-17 | 2012-12-20 | Shl Group Ab | Injection device |
| ES2936387T3 (es) * | 2011-10-31 | 2023-03-16 | Hoffmann La Roche | Formulaciones de anticuerpos anti-il13 |
| PT3889181T (pt) | 2012-09-07 | 2024-05-29 | Regeneron Pharma | Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração |
| JP2016522168A (ja) | 2013-04-05 | 2016-07-28 | ジェネンテック， インコーポレイテッド | 抗ｉｌ−４抗体及び二重特異性抗体及びその使用 |
| CA2937387A1 (en) * | 2014-01-27 | 2015-07-30 | Medimmune, Llc | Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lung |
| MX2017011486A (es) | 2015-03-16 | 2018-06-15 | Genentech Inc | Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2. |
| PT3528838T (pt) * | 2016-09-23 | 2023-09-04 | Hoffmann La Roche | Utilizações de antagonistas de il-13 para tratamento de dermatite atópica |
-
2017
- 2017-09-22 PT PT177802808T patent/PT3528838T/pt unknown
- 2017-09-22 UA UAA201902409A patent/UA124269C2/uk unknown
- 2017-09-22 HR HRP20231015TT patent/HRP20231015T1/hr unknown
- 2017-09-22 PL PL17780280.8T patent/PL3528838T3/pl unknown
- 2017-09-22 KR KR1020197007162A patent/KR102557643B1/ko active Active
- 2017-09-22 WO PCT/US2017/052891 patent/WO2018057849A1/en not_active Ceased
- 2017-09-22 TW TW106132523A patent/TWI787203B/zh active
- 2017-09-22 CA CA3031589A patent/CA3031589C/en active Active
- 2017-09-22 SI SI201731388T patent/SI3528838T1/sl unknown
- 2017-09-22 CN CN201780058200.4A patent/CN109715201A/zh active Pending
- 2017-09-22 NZ NZ790629A patent/NZ790629A/en unknown
- 2017-09-22 RS RS20230712A patent/RS64550B1/sr unknown
- 2017-09-22 EP EP17780280.8A patent/EP3528838B1/en active Active
- 2017-09-22 LT LTEPPCT/US2017/052891T patent/LT3528838T/lt unknown
- 2017-09-22 IL IL265473A patent/IL265473B2/en unknown
- 2017-09-22 HU HUE17780280A patent/HUE063135T2/hu unknown
- 2017-09-22 ES ES17780280T patent/ES2958593T3/es active Active
- 2017-09-22 EP EP23182855.9A patent/EP4268845A3/en active Pending
- 2017-09-22 AU AU2017330405A patent/AU2017330405B2/en active Active
- 2017-09-22 RU RU2019103943A patent/RU2752785C2/ru active
- 2017-09-22 FI FIEP17780280.8T patent/FI3528838T3/fi active
- 2017-09-22 JP JP2019515636A patent/JP6995844B2/ja active Active
- 2017-09-22 SG SG11201900845YA patent/SG11201900845YA/en unknown
- 2017-09-22 DK DK17780280.8T patent/DK3528838T5/da active
- 2017-09-22 MX MX2019002672A patent/MX2019002672A/es unknown
-
2019
- 2019-03-18 US US16/356,309 patent/US11434286B2/en active Active
-
2022
- 2022-08-08 US US17/882,932 patent/US20220372131A1/en active Pending
-
2023
- 2023-09-13 CY CY20231100495T patent/CY1126255T1/el unknown
-
2024
- 2024-03-21 US US18/612,141 patent/US20240228606A1/en active Pending
- 2024-04-29 NL NL301269C patent/NL301269I2/nl unknown
- 2024-04-29 LT LTPA2024512C patent/LTC3528838I2/lt unknown
- 2024-04-29 FR FR24C1017C patent/FR24C1017I2/fr active Active
- 2024-04-30 FI FIC20240013C patent/FIC20240013I1/fi unknown
- 2024-04-30 HU HUS2400011C patent/HUS2400011I1/hu unknown
- 2024-05-29 CY CY2024013C patent/CY2024013I1/el unknown